Puma Biotechnology, Inc.
PBYI· Nasdaq
PBYIPuma Biotechnology, Inc.
Filed Feb 29, 2024 · 10-K · 60 days after period end · 0001437749-24-006121
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $72.18M | $65.68M | $55.36M | $52.56M |
| Net Income | $12.27M | -$5.61M | $4.12M | -$14.99M |
| EPS Diluted | — | — |
Puma Biotechnology, Inc. · CIK 1401667 · Engraved from SEC EDGAR
| — |
| -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 29, 2024 · 60 d after period end
